An overview of the rare parotid gland cancer

Head and Neck Oncology

Volumn 3, Issue 1, 2011, Pages

  Ho, Kimberley ^a   Lin, Helen ^a   Ann, David K ^a   Chu, Peiguo G ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

endosomal sorting complexes required for transport; epidermal growth factor receptor; multi vesicular bodies; Parotid gland cancer; salivary gland cancer; targeted therapeutics; vacuolar protein sorting associated protein 4B; vascular endothelial growth factor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOXANTRONE; NAVELBINE; NITROSO DERIVATIVE; PACLITAXEL; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

ADENOSQUAMOUS CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CARCINOGENESIS; FACIAL NERVE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; NONHUMAN; OCCUPATIONAL EXPOSURE; PAROTID GLAND CANCER; PAROTIDECTOMY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION EXPOSURE; REVIEW; RISK FACTOR; RUBBER INDUSTRY; ANIMAL; PAROTID GLAND; PAROTID GLAND TUMOR; PATHOLOGY; PROGNOSIS;

ANIMALS; HUMANS; PAROTID GLAND; PAROTID NEOPLASMS; PROGNOSIS;

EID: 80052869608     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-3-40     Document Type: Review

References (45)

1. th July 2011
2. th July 2011
3. Incidence of salivary gland cancer in the United States relative to ultraviolet radiation exposure. Spitz MR, Sider JG, Newell GR, Batsakis JG, Head Neck Surg 1988 10 205 308
4. th July 2011
5. th July 2011
6. Rubin R, Strayer DS, (eds), Rubin's Pathology: Clinicopathologic Foundations of Medicine Lippincott Williams & Wilkins, Maryland 4 2004 1283 85 21922616
7. th July 2011
8. th July 2011
9. Salivary gland tumors among atomic bomb survivors, 1950-1987. Saku T, Hayashi Y, Takahara O, et al. Cancer 1997 79 1465 75 10.1002/(SICI)1097- 0142(19970415)79:8<1465::AID-CNCR4>3.0.CO;2-A 9118025 (Pubitemid 27154774)
10. Risk factors for major salivary gland carcinoma: a case-comparison study. Spitz MR, Tilley BC, Batsakis JG, Gibeau JM, Newell GR, Cancer 1984 54 1854 1859 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1 6478421 (Pubitemid 14020615)
11. Salivary gland neoplasms as a late consequence of head and neck irradiation. Schneider AB, Favus MJ, Stachura ME, Ann Intern Med 1977 87 160 164 889197 (Pubitemid 8165579)
12. Environmental factors and the risk of salivary gland cancer. Horn-Ross PL, Ljung BM, Morrow M, Epidemiology 1997 8 4 414 419 10.1097/00001648- 199707000-00011 9209856 (Pubitemid 27274228)
13. Epidemiological considerations of cancer of the gallbladder, bile ducts and salivary glands in the rubber industry. Mancuso TF, Brennan MJ, Journal of Occup Med 1970 12 333 341
14. Tumors of the major and minor salivary glands. McKenna RJ, CA Cancer J Clin 1984 34 1 24 39 10.3322/canjclin.34.1.24 6420017 (Pubitemid 14190998)
15. Malignant Diseases of the Salivary Glands. Lalwani Anil K, Current diagnosis & treatment in otolaryngology: head & neck surgery McGraw-Hill Medical 2008 Chapter 18 21922533
16. Structural and mechanistic studies of VPS4 proteins. Scott A, Chung H, Gonciarz-Swiatek M, et al. The European Molecular Biology Organization Journal 2005 24 20 3658 3668
17. Cell signaling by receptor tyrosine kinases. Schlessinger J, Cell 2000 103 211 225 10.1016/S0092-8674(00)00114-8 11057895
18. Receptor tyrosine kinases: specific outcomes from general signals. Simon MA, Cell 2000 103 13 15 10.1016/S0092-8674(00)00100-8 11051543
19. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Li E, Hristova K, Biochemistry 45 20 6241 51
20. Signal transduction and endocytosis: close encounters of many kinds. Sorkin A, Von Zastrow M, Nut Rev Mol Cell Biol 2002 3 600 614 10.1038/nrm883
21. Receptor downregulation and multivesicular-body sorting. Katzmann DJ, Odorizzi G, Emr SD, Nut Rev Mol Cell Biol 2002 3 893 905 10.1038/nrm973 (Pubitemid 35477368)
22. Macroautophagy signaling and regulation. Esclatine A, Chaumorcel M, Codogno P, Curr Top Microbiol Immunol 2009 335 33 70 10.1007/978-3-642-00302-8-2 19802559
23. AAA+ ATPases: achieving diversity of function with conserved machinery. White SR, Lauring B, Traffic 2007 8 1657 1667 10.1111/j.1600-0854.2007.00642.x 17897320 (Pubitemid 350066678)
24. Autophagy as a regulated pathway of cellular degradation. Klionsky DJ, Emr SD, Science 2000 290 1717 1721 11099404 (Pubitemid 32004796)
25. ESCRTs and Fabl regulate distinct steps of autophagy. Rusten TE, Vaccari T, Lindmo K, Curr Biol 2007 17 1817 1825 10.1016/j.cub.2007.09.032 17935992 (Pubitemid 47576670)
26. Autophagy and tumorigenesis. Chen N, Debnath J, Federation of European Biochemical Societies Letters 2010 584 1427 1435 10.1016/j.febslet.2009.12.034 20035753
27. A census of amplified and overexpressed human cancer genes. Santarius T, Shipley J, Brewer D, Nut Rev Cancer 2010 10 59 64 10.1038/nrc2771
28. Neutron versus photon irradiation for unresectable salivary gland tumors: Final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Laramore GE, Krall JM, Griffin TW, et al. Int J Radiat Oncol Biol Phys 1993 27 2 235 240 10.1016/0360-3016(93)90233-L 8407397 (Pubitemid 23304448)
29. Fast neutron radiotherapy. Stelzer KJ, Laramore GE, Griffin TW, et al. The University of Washington experience. Acta Oncol 1994 33 3 275 80
30. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Huber PE, Debus J, Latz D, et al. Radiother Oncol 2001 59 2 161 7 10.1016/S0167-8140(00)00273-5 11325445 (Pubitemid 32452309)
31. Systemic therapy in the palliative management of advanced salivary gland cancers. Laurie SA, Licitra L, J Clin Oncol 2006 24 17 2673 8 10.1200/JCO.2005.05.3025 16763282 (Pubitemid 46622089)
32. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Airoldi M, Pedani F, Succo G, et al. Cancer 2001 91 3 541 7 10.1002/1097-0142(20010201)91: 3<541::AID-CNCR1032>3.0.CO;2-Y 11169936 (Pubitemid 32105699)
33. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Licitra L, Marchini S, Spinazzè S, et al. Cancer 1991 68 1874 1877 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S 1913539
34. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Gilbert J, Li Y, Pinto HA, Jennings T, et al. Head Neck 2006 28 3 197 204 10.1002/hed.20327 16470745 (Pubitemid 43269885)
35. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Gedlicka C, Schüll B, Formanek M, et al. Anticancer Drugs 2002 13 5 491 5 10.1097/00001813-200206000-00007 12045460 (Pubitemid 34621053)
36. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D, Cancer 1987 60 2869 2872 10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y 2824016 (Pubitemid 18005856)
37. Adriamycin/cis-platinum/Cyclophosphamide Combination Chemotherapy for Advanced Carcinoma of the Parotid Gland. Alberts DS, Manning MR, Coulthard SW, Koopmann CF Jr, Herman TS, Cancer 1981 47 4 645 8 10.1002/1097-0142(19810215)47: 4<645::AID-CNCR2820470404>3.0.CO;2-A 7194729
38. Docetaxel (Taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H, Oral Oncol 2004 40 2 5 7 (Pubitemid 41151944)
39. Concurrent chemoradiotherapy for locally advanced nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. Brizel DM, Esclamado R, J Clin Oncol 2006 24 2612 2617 10.1200/JCO.2005.05.2829 16763273 (Pubitemid 46622081)
40. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers. Version 1.2011. NCCN.org National Comprehensive Cancer Network. lnc 2011 http://www.nccn.org/professionals/physician-gls/pdf/head-and-neck.pdf Last accessed 26th July 2011
41. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, (eds), American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Manual New York, Berlin, Heidelberg: Springer-Verlag 7 2010
42. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. van de Water TA, Lomax AJ, Bijl HP, et al. Int J Radiat Oncol Biol Phys 2011 79 4 1216 24 Epub 2010 10.1016/j.ijrobp.2010.05.012 20732761
43. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Bonner JA, Harari PM, Giralt J, et al. Lancet Oncol 2010 11 1 21 8 Epub 2009 10.1016/S1470-2045(09)70311-0 19897418
44. A phase II study erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Cohen EE, Davis DW, Karrison TG, et al. Lancet Oncol 2009 10 3 247 57 10.1016/S1470-2045(09)70002-6 19201650
45. Distant metastasis of parotid gland tumors. Schwentner I, Obrist P, Thumfart W, Sprinzl G, Acta Otolaryngol 2006 126 4 340 5 10.1080/ 00016480500401035 16608783